136 related articles for article (PubMed ID: 34407053)
1. The power of kindness: curative treatment with metronomic combination in advanced hepatocellular carcinoma.
Brandi G; Di Federico A; Rizzo A; De Lorenzo S; Vasuri F; Brocchi S; Golfieri R; Morelli MC; Frega G; Palloni A
Anticancer Drugs; 2022 Jan; 33(1):e781-e783. PubMed ID: 34407053
[TBL] [Abstract][Full Text] [Related]
2. Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases.
Brandi G; Venturi M; De Lorenzo S; Garuti F; Frega G; Palloni A; Garajovà I; Abbati F; Saccoccio G; Golfieri R; Pantaleo MA; Barbera MA
Cancer Commun (Lond); 2018 Jun; 38(1):41. PubMed ID: 29941039
[TBL] [Abstract][Full Text] [Related]
3. Long-lasting response with metronomic capecitabine in advanced hepatocellular carcinoma.
Ballardini P; Marri I; Margutti G; Aliberti C; Benea G; Manfredini R
Tumori; 2010; 96(5):768-70. PubMed ID: 21302626
[TBL] [Abstract][Full Text] [Related]
4. Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study.
Brandi G; de Rosa F; Agostini V; di Girolamo S; Andreone P; Bolondi L; Serra C; Sama C; Golfieri R; Gramenzi A; Cucchetti A; Pinna AD; Trevisani F; Biasco G;
Oncologist; 2013; 18(12):1256-7. PubMed ID: 24232581
[TBL] [Abstract][Full Text] [Related]
5. Durable complete response of hepatocellular carcinoma after metronomic capecitabine.
Brandi G; de Rosa F; Bolondi L; Agostini V; Di Girolamo S; Nobili E; Biasco G
Tumori; 2010; 96(6):1028-30. PubMed ID: 21388070
[TBL] [Abstract][Full Text] [Related]
6. Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial.
Walter I; Schulz U; Vogelhuber M; Wiedmann K; Endlicher E; Klebl F; Andreesen R; Herr W; Ghibelli L; Hackl C; Wiest R; Reichle A
Med Oncol; 2017 Nov; 34(12):192. PubMed ID: 29098441
[TBL] [Abstract][Full Text] [Related]
7. The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation.
Ravaioli M; Cucchetti A; Pinna AD; De Pace V; Neri F; Barbera MA; Maroni L; Frega G; Palloni A; De Lorenzo S; Ripoli MC; Pantaleo MA; Cescon M; Del Gaudio M; Brandi G
Sci Rep; 2017 Sep; 7(1):11305. PubMed ID: 28900245
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy of metronomic chemotherapy after cool-tip radiofrequency ablation in the treatment of hepatocellular carcinoma.
Wang-Yuan Z; Jiang-Zheng Z; Lu YD; Hao XB; Hong T; Huang F; Lei JH; He ZH; Huang MZ
Int J Hyperthermia; 2016; 32(2):193-8. PubMed ID: 26586093
[TBL] [Abstract][Full Text] [Related]
9. Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure.
Granito A; Marinelli S; Terzi E; Piscaglia F; Renzulli M; Venerandi L; Benevento F; Bolondi L
Dig Liver Dis; 2015 Jun; 47(6):518-22. PubMed ID: 25861840
[TBL] [Abstract][Full Text] [Related]
10. Capecitabine in advanced hepatocellular carcinoma: A multicenter experience.
Pelizzaro F; Sammarco A; Dadduzio V; Pastorelli D; Giovanis P; Soldà C; Rizzato MD; Lombardi G; Lonardi S; Peserico G; Imondi A; Sartori A; Maddalo G; Farinati F
Dig Liver Dis; 2019 Dec; 51(12):1713-1719. PubMed ID: 31320302
[TBL] [Abstract][Full Text] [Related]
11. Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation.
Trevisani F; Brandi G; Garuti F; Barbera MA; Tortora R; Casadei Gardini A; Granito A; Tovoli F; De Lorenzo S; Inghilesi AL; Foschi FG; Bernardi M; Marra F; Sacco R; Di Costanzo GG
J Cancer Res Clin Oncol; 2018 Feb; 144(2):403-414. PubMed ID: 29249005
[TBL] [Abstract][Full Text] [Related]
12. Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study.
Casadei Gardini A; Foca F; Scartozzi M; Silvestris N; Tamburini E; Faloppi L; Brunetti O; Rudnas B; Pisconti S; Valgiusti M; Marisi G; Foschi FG; Ercolani G; Tassinari D; Cascinu S; Frassineti GL
Sci Rep; 2017 Feb; 7():42499. PubMed ID: 28211921
[TBL] [Abstract][Full Text] [Related]
13. Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08-20.
Patt Y; Rojas-Hernandez C; Fekrazad HM; Bansal P; Lee FC
Oncologist; 2017 Oct; 22(10):1158-e116. PubMed ID: 28687627
[TBL] [Abstract][Full Text] [Related]
14. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.
Chen YP; Liu X; Zhou Q; Yang KY; Jin F; Zhu XD; Shi M; Hu GQ; Hu WH; Sun Y; Wu HF; Wu H; Lin Q; Wang H; Tian Y; Zhang N; Wang XC; Shen LF; Liu ZZ; Huang J; Luo XL; Li L; Zang J; Mei Q; Zheng BM; Yue D; Xu J; Wu SG; Shi YX; Mao YP; Chen L; Li WF; Zhou GQ; Sun R; Guo R; Zhang Y; Xu C; Lv JW; Guo Y; Feng HX; Tang LL; Xie FY; Sun Y; Ma J
Lancet; 2021 Jul; 398(10297):303-313. PubMed ID: 34111416
[TBL] [Abstract][Full Text] [Related]
15. Metronomic capecitabine as maintenance treatment after first line induction with XELOX for metastatic colorectal cancer patients.
Geng R; Wang G; Qiu L; Liu B; Yang F; Zhang J; Miao Y
Medicine (Baltimore); 2020 Dec; 99(51):e23719. PubMed ID: 33371122
[TBL] [Abstract][Full Text] [Related]
16. Systemic therapies in elderly patients with advanced hepatocellular carcinoma: Do not forget metronomic capecitabine.
Wilhelmi M
Eur J Surg Oncol; 2021 Aug; 47(8):2208. PubMed ID: 33906788
[No Abstract] [Full Text] [Related]
17. Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept.
De Lorenzo S; Tovoli F; Barbera MA; Garuti F; Palloni A; Frega G; Garajovà I; Rizzo A; Trevisani F; Brandi G
Sci Rep; 2018 Jul; 8(1):9997. PubMed ID: 29968763
[TBL] [Abstract][Full Text] [Related]
18. Activity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma.
Ang SF; Tan SH; Toh HC; Poon DY; Ong SY; Foo KF; Choo SP
Am J Clin Oncol; 2012 Jun; 35(3):222-7. PubMed ID: 21378539
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine for treatment of advanced hepatocellular carcinoma.
von Delius S; Lersch C; Mayr M; Stock K; Schulte-Frohlinde E; Schmid RM; Eckel F
Hepatogastroenterology; 2007 Dec; 54(80):2310-4. PubMed ID: 18265654
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of metronomic chemotherapy for patients with advanced primary hepatocellular carcinoma with major portal vein tumor thrombosis.
Woo HY; Youn JM; Bae SH; Jang JW; Cha JH; Kim HL; Chun HJ; Choi BG; Choi JY; Yoon SK
Korean J Hepatol; 2012 Mar; 18(1):32-40. PubMed ID: 22511901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
